104 related articles for article (PubMed ID: 29608461)
1. Vilazodone efficacy in subgroups of patients with major depressive disorder: a post-hoc analysis of four randomized, double-blind, placebo-controlled trials.
Kornstein S; Chang CT; Gommoll CP; Edwards J
Int Clin Psychopharmacol; 2018 Jul; 33(4):217-223. PubMed ID: 29608461
[TBL] [Abstract][Full Text] [Related]
2. Evaluating the efficacy of vilazodone in achieving remission in patients with major depressive disorder: post-hoc analyses of a phase IV trial.
Citrome L; Gommoll CP; Tang X; Nunez R; Mathews M
Int Clin Psychopharmacol; 2015 Mar; 30(2):75-81. PubMed ID: 25396353
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of vilazodone 20 and 40 mg in major depressive disorder: a randomized, double-blind, placebo-controlled trial.
Mathews M; Gommoll C; Chen D; Nunez R; Khan A
Int Clin Psychopharmacol; 2015 Mar; 30(2):67-74. PubMed ID: 25500685
[TBL] [Abstract][Full Text] [Related]
4. Vilazodone in the treatment of major depressive disorder: efficacy across symptoms and severity of depression.
Khan A; Sambunaris A; Edwards J; Ruth A; Robinson DS
Int Clin Psychopharmacol; 2014 Mar; 29(2):86-92. PubMed ID: 24247740
[TBL] [Abstract][Full Text] [Related]
5. The efficacy of extended-release levomilnacipran in moderate to severe major depressive disorder: secondary and post-hoc analyses from a randomized, double-blind, placebo-controlled study.
Montgomery SA; Mansuy L; Ruth AC; Li D; Gommoll C
Int Clin Psychopharmacol; 2014 Jan; 29(1):26-35. PubMed ID: 24172160
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Esmethadone (REL-1017) in Patients With Major Depressive Disorder and Inadequate Response to Standard Antidepressants: A Phase 3 Randomized Controlled Trial.
Fava M; Stahl SM; Pani L; De Martin S; Cutler AJ; Maletic V; Gorodetzky CW; Vocci FJ; Sapienza FL; Kosten TR; Kröger C; Champasa P; O'Gorman C; Guidetti C; Alimonti A; Comai S; Mattarei A; Folli F; Bushnell D; Traversa S; Inturrisi CE; Manfredi PL; Pappagallo M
J Clin Psychiatry; 2024 Jun; 85(3):. PubMed ID: 38917366
[No Abstract] [Full Text] [Related]
7. Esketamine versus placebo on time to remission in major depressive disorder with acute suicidality.
Fu DJ; Zhang Q; Shi L; Borentain S; Guo S; Mathews M; Anjo J; Nash AI; O'Hara M; Canuso CM
BMC Psychiatry; 2023 Aug; 23(1):587. PubMed ID: 37568081
[TBL] [Abstract][Full Text] [Related]
8. A 6-week, phase IIb, randomized, double-blind, placebo-controlled trial of Anyu Peibo capsules for the treatment of major depressive disorder in adults.
He S; Yu Y; Huang J; Yin J; Niu Y; Lu Y; Wu B; Fang M; Wang X; Tao Z; Li L; Li K; Li Y; Ding X; Shen Y; Li H
Ther Adv Psychopharmacol; 2023; 13():20451253231212342. PubMed ID: 38022835
[TBL] [Abstract][Full Text] [Related]
9. Effect of Time From Onset of Major Depressive Disorder on the Therapeutic Response to Esmethadone (REL-1017).
Guidetti C; De Martin S; Serra G; Apicella M; Pani L; Pappagallo M; Mattarei A; Folli F; Manfredi P; Fava M
J Clin Psychiatry; 2024 May; 85(2):. PubMed ID: 38767937
[No Abstract] [Full Text] [Related]
10. Esketamine vs Midazolam in Boosting the Efficacy of Oral Antidepressants for Major Depressive Disorder: A Pilot Randomized Clinical Trial.
Xiao C; Zhou J; Li A; Zhang L; Zhu X; Zhou J; Hu Y; Zheng Y; Liu J; Deng Q; Wang H; Wang G
JAMA Netw Open; 2023 Aug; 6(8):e2328817. PubMed ID: 37578792
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of cariprazine in patients with bipolar depression and higher or lower levels of baseline anxiety: a pooled post hoc analysis.
Jain R; McIntyre RS; Cutler AJ; Earley WR; Nguyen HB; Adams JL; Yatham LN
Int Clin Psychopharmacol; 2024 Mar; 39(2):82-92. PubMed ID: 37551609
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of cariprazine in bipolar I depression across patient characteristics: a post hoc analysis of pooled randomized, placebo-controlled studies.
Patel M; Jain R; Tohen M; Maletic V; Earley WR; Yatham LN
Int Clin Psychopharmacol; 2021 Mar; 36(2):76-83. PubMed ID: 33230026
[TBL] [Abstract][Full Text] [Related]
13. A Randomized Controlled Trial Comparing Efficacy and Safety of Antidepressant Monotherapy.
Santi NS; Biswal SB; Naik BN; Sahoo JP; Rath B
Cureus; 2024 Apr; 16(4):e59074. PubMed ID: 38800340
[TBL] [Abstract][Full Text] [Related]
14. Examining the efficacy of adjunctive aripiprazole in major depressive disorder: a pooled analysis of 2 studies.
Thase ME; Trivedi MH; Nelson JC; Fava M; Swanink R; Tran QV; Pikalov A; Yang H; Carlson BX; Marcus RN; Berman RM
Prim Care Companion J Clin Psychiatry; 2008; 10(6):440-7. PubMed ID: 19287552
[TBL] [Abstract][Full Text] [Related]
15. Using prefrontal and midline right frontal EEG-derived theta cordance and depressive symptoms to predict the differential response or remission to antidepressant treatment in major depressive disorder.
de la Salle S; Jaworska N; Blier P; Smith D; Knott V
Psychiatry Res Neuroimaging; 2020 Aug; 302():111109. PubMed ID: 32480044
[TBL] [Abstract][Full Text] [Related]
16. Replication of scopolamine's antidepressant efficacy in major depressive disorder: a randomized, placebo-controlled clinical trial.
Drevets WC; Furey ML
Biol Psychiatry; 2010 Mar; 67(5):432-8. PubMed ID: 20074703
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of aticaprant, a kappa receptor antagonist, adjunctive to oral SSRI/SNRI antidepressant in major depressive disorder: results of a phase 2 randomized, double-blind, placebo-controlled study.
Schmidt ME; Kezic I; Popova V; Melkote R; Van Der Ark P; Pemberton DJ; Mareels G; Canuso CM; Fava M; Drevets WC
Neuropsychopharmacology; 2024 Apr; ():. PubMed ID: 38649428
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Hamilton Depression Rating Scale and Montgomery-Åsberg Depression Rating Scale: Baked Straight From a Randomized Study.
Santi NS; Biswal SB; Naik BN; Sahoo JP; Rath B
Cureus; 2023 Sep; 15(9):e45098. PubMed ID: 37842359
[TBL] [Abstract][Full Text] [Related]
19. Dextromethorphan-Bupropion for the Treatment of Depression: A Systematic Review of Efficacy and Safety in Clinical Trials.
Akbar D; Rhee TG; Ceban F; Ho R; Teopiz KM; Cao B; Subramaniapillai M; Kwan ATH; Rosenblat JD; McIntyre RS
CNS Drugs; 2023 Oct; 37(10):867-881. PubMed ID: 37792265
[TBL] [Abstract][Full Text] [Related]
20. Youth Depression Alleviation-Augmentation with an anti-inflammatory agent (YoDA-A): protocol and rationale for a placebo-controlled randomized trial of rosuvastatin and aspirin.
Quinn AL; Dean OM; Davey CG; Kerr M; Harrigan SM; Cotton SM; Chanen AM; Dodd S; Ratheesh A; Amminger GP; Phelan M; Williams A; Mackinnon A; Giorlando F; Baird S; Rice S; O'Shea M; Schäfer MR; Mullen E; Hetrick S; McGorry P; Berk M
Early Interv Psychiatry; 2018 Feb; 12(1):45-54. PubMed ID: 26542332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
